Glioblastoma
  • Featured content
    Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
  • Featured content
    In this downloadable slideset, Margaret Callahan, MD, PhD; Shirish Gadgeel, MD; Ryan T. Merrell, MD; Bradley J. Monk, MD, FACS, FACOG; and Joyce O’Shaughnessy, MD, review important clinical presentations across multiple cancers from the 2016 oncology meeting in Copenhagen.
    Date Posted: 12/12/2016
  • Featured content
    Ravi Salgia, MD, provides expert perspective on results of studies of MET-targeted agents being evaluated in a variety of tumor types.
  • Featured content
    Ahmad Tarhini, MD, PhD, reviews the role of the VEGF pathway in oncogenesis and explores studies of VEGF-targeted agents and potential biomarkers in multiple tumor types.
  • Featured content
    In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
    Date Posted: 4/14/2017
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

8 of 8 Shown
8 of 8 Shown
Show 0 More
Loading...